Genome Engineering Market expected to reach US$ 8,512.5 Mn by 2025 at CAGR of 14.3% during forecast period 2019 to 2025 | Coherent Market Insights
The global genome engineering market was evaluated at US$ 2,582.7 million in 2016 and is projected to register a magnificent CAGR of 14.3% over the forecast period (2017-2025).
The introduction of novel technologies in genome engineering is a pivotal aspect accelerating the growth of global genome engineering market. In 2017, Synthego Corporation launched its CRISPRevolution Gene Knockout Kit (GKO), with the first guaranteed CRISPR gene editing solution. The new Synthego’s kits rapidly modifies difficult-to-edit human hematopoietic stem cells, as well as primary T cells, in a cost-effective manner.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/1262
Global Genome Engineering Market- Insights
Genome engineering is the synthetic assembly of complete chromosomal DNA that is more or less derived from natural genomic sequences. There are two types of gene therapy namely Ex-Vivo Gene Therapy and In-Vivo Gene Therapy. In Ex-vivo gene therapy, genes are transferred into cultured cells and then reintroduced in patient, On the contrary, in In-vivo gene therapy, genes are directly delivered in cells of a particular tissue. Key companies such as CRISPR Therapeutics AG, Editas Medicine, Inc., and Intellia Therapeutics, Inc. are focusing on developing In-Vivo and Ex-vivo gene therapy. Major techniques used in genome engineering are CRISPR, TALEN, and ZFN. CRISPR (CRISPR-Cas9). Moreover, there novel genome editing tools available for researchers to edit parts of the genome by adding, removing, or altering sections of the DNA sequence. In which, CRISPR is an accurate, faster, and cheaper technique for editing DNA as compared to others methods such as TALEN and ZFN. Transcription activator-like effector nucleases (TALEN) is a technology widely used in live cell gene editing. Zinc-finger nucleases (ZFNs) is an artificial restriction enzyme, which simplifies targeted editing of genome by creating double-strand breaks in DNA at user-specified locations.
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1262
Market Dynamics- Drivers
Increasing development of novel technologies in genome engineering is expected to drive growth of the global genome engineering market in the near future
Introduction of novel technologies in genome engineering by key market players is expected to drive growth of the global genome engineering market during the forecast period. For instance, in February 2018, Sangamo Therapeutics, Inc. received clinical trial authorization (CTA) from Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for its SB-FIX, a zinc finger nuclease (ZFN)-mediated in-vivo genome editing treatment for hemophilia B. CTA has allowed for the beginning of Europe’s first in-vivo genome editing study. In 2017, Integrated DNA Technologies, Inc. launched the first Cas9 enzyme variant, which reduces off-target effects in CRISPR genome editing. The launch of latest Cas9 enzyme variant is a major step towards therapeutic use of CRISPR. In 2017, Scientists at Salk Institute for Biological Studies, modified CRISPR to epigenetically treat diabetes, kidney disease, and muscular dystrophy. They developed a latest version of CRISPR/Cas9 genome editing technology, which allows for activation of genes without creating breaks in the DNA. Therefore, advancement in technologies is expected to propel the global genome engineering market growth over the forecast period.
The global genome engineering market was valued at US$ 2,582.7 Mn in 2016 and is expected to witness a CAGR of 14.3% over the forecast period (2017–2025).
Figure 1. Global Genome Engineering Market Share (%), By Technology, 2017–2025
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/genome-engineering-market-to-surpass-us-85125-mn-threshold-by-2025-577
Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth in the near future
Key players in the market are involved in various growth strategies such as collaborations, agreement, and partnerships, in order to gain competitive edge in the market. For instance, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, entered into collaborative agreement with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. will use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering. In 2016, CRISPR Therapeutics and Bayer AG collaborated and formed a joint venture Casebia Therapeutics, for developing CRISPR-based therapeutics in select disease areas. Moreover, in 2017, Casebia Therapeutics collaborated with CureVac AG. According to collaborative agreement, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications. In 2015, AstraZeneca plc entered into research collaborations with The Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and Broad Institute/Whitehead Institute to use their CRISPR technology for genome editing. Such strategic collaborations among major key players and research institutes is expected to drive market growth in the near future.
Moreover, increasing funding and investments for the development and research of new genetic engineering technologies is also expected to drive market growth. For instance, in January 2018, the U.S. National Institutes of Health (NIH) announced to grant US$ 190 million for genome editing research. This new program, Somatic Cell Genome Editing, will award funds to biomedical researchers over the following six years. The support from major research organizations such as NIH is expected to attract more researchers in this field, which may lead to advancements in technology and also aid in growth of the market.
Market Dynamics- Restraints
High cost associated with genome engineering technologies is expected restrain growth of the global genome engineering market over the forecast period. For instance, according to the fees chart provided by Yale Genome Editing Center, in 2018, it charges between US$ 8,000 and US$ 15,000 for gene editing facilities. The high cost associated with genome engineering facilities is expected to hamper the market growth, especially in emerging economies such as India, Brazil, and South Africa. Moreover, genome engineering is a very complex technology and needs high skilled researchers, which limits its adoption rate.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1262
Competitive Landscape
Key players operating in the global genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.
Detailed Segmentation:
- Global Genome Engineering Market, By Technology :
- CRISPR
- TALEN
- ZFN
- Others
- Global Genome Engineering Market, By Application:
- Cell Line Engineering
- Genetic Engineering
- Global Genome Engineering Market, By End User:
- Biotechnology & Pharmaceutical Companies
- Research Institutes
- Contract Research Organization
Other Related News:
About Us:Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.
Editor Details
-
Company:
- CDN Newswire
